Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Analysts' Corner
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, October 11, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Biogen Idec Inc. (NASDAQ: BIIB), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Medivation, Inc. (NASDAQ: MDVN), Agenus Inc. (NASDAQ: AGEN), and Arrowhead Research Corp. (NASDAQ: ARWR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Biogen Idec Inc. Research Report
On October 7, 2013, Biogen Idec Inc. (Biogen Idec) announced that it will release its Q3 2013 financial results on Monday, October 28, 2013, before the market opens. Biogen Idec reported that it will also host a live webcast, wherein the Company's management will discuss the financial results on the same day at 9:00 a.m. ET. The Company further notified that interested parties can access the live webcast of the call through its Investor Relations website, wherein Biogen Idec will also make an archived version of the call available for 30 days. The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/b95b_BIIB]
Questcor Pharmaceuticals, Inc. Research Report
On October 8, 2013, Questcor Pharmaceuticals, Inc. (Questcor) announced that it will release its Q3 2013 financial results after the market closes on Tuesday, October 29, 2013. Questcor informed that it will also host a conference call and slide presentation via webcast on the same day at 4:30 p.m. ET (1:30 p.m. PT), to discuss the results and highlights of the quarter, as well as its current corporate developments. The Company stated that the webcast will be available through its Investor Relations website, while an audio replay of the call will be accessible for seven business days by dialing the numbers available at the Company's website. The Full Research Report on Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/a415_QCOR]
Medivation, Inc. Research Report
On September 26, 2013, Medivation, Inc. (Medivation) and Astellas Pharma US, Inc. announced results of a national survey of men with advanced prostate cancer and their caregivers. According to Medivation, though the patients who participated in the survey are generally optimistic, a good number among them may feel isolated in coping with their disease. The companies reported that 45% of the participants said that they keep silent about their prostate cancer and treatments, and 59% have shown concern about becoming a burden to family and friends, while 43% of patient respondents have the same level of concern about dying. Thomas A. Farrington, Founder and President of Prostate Health Education Network (PHEN), commented, "This survey provides much-needed information that will help us better support them, particularly as there is evidence that men are now living longer with advanced disease." The Full Research Report on Medivation, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/4277_MDVN]
Agenus Inc. Research Report
On October 7, 2013, Agenus Inc. (Agenus) announced that new Phase 3 data for GlaxoSmithKline's (GSK's) RTS,S malaria vaccine candidate, which contains Agenus' QS-21 Stimulon1 adjuvant, were presented at a Multilateral Initiative on Malaria Pan African Conference in Durban, South Africa. Agenus informed that RTS,S helps to protect young children and infants from clinical malaria up to 18 months post vaccination. Garo H. Armen, Ph.D., Chairman and CEO of Agenus, commented, "These findings indicate that RTS,S has the potential to help prevent millions of malaria cases. We are very pleased that our QS-21 Stimulon adjuvant is a key component of AS01, a proprietary adjuvant system used in RTS,S." Armen continued, "These results provide further support that QS-21 Stimulon can help advance challenging development programs targeting difficult diseases. Currently there are 21 development programs underway involving vaccines that include QS-21 Stimulon for many different types of cancer, infectious diseases and degenerative disorders." The Full Research Report on Agenus Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/c668_AGEN]
Arrowhead Research Corp. Research Report
On October 8, 2013, Arrowhead Research Corp. (Arrowhead) announced that it has successfully completed enrollment of 36 subjects in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection. According to Arrowhead, initial data indicate that ARC-520 is generally safe and well tolerated at all six dose levels studied, enabling the Company to proceed with plans to initiate a Phase 2a pilot efficacy study in chronic HBV patients. Christopher Anzalone, Ph.D., President and CEO of Arrowhead, said, "We are very pleased with these results and the pace at which we were able to complete the Phase 1 study. This positive readout on safety and tolerability of ARC-520 and the Dynamic Polyconjugate (DPC) delivery platform has broad implications for Arrowhead. It gives us additional confidence as we move into an upcoming Phase 2a study and we believe it represents a key de-risking event for expanding our pipeline of RNAi therapeutics based on the DPC platform." The Full Research Report on Arrowhead Research Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/0c95_ARWR]
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.